GENITAL TALC EXPOSURE AND RISK OF OVARIAN CANCER

Daniel W. Cramer¹*, Rebecca F. Liberman¹, Linda Titus-Ernstoff², William R. Welch³, E. Robert Greenberg², John A. Baron² and Bernard L. Harlow¹

¹Obstetrics-Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA

²Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA

³Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

Epidemiologic studies have suggested an increased risk for ovarian cancer associated with the use of talcum powder in genital hygiene, but the biologic credibility of the association has been questioned. We conducted a population-based case-control study in eastern Massachusetts and New Hampshire involving 563 women with newly diagnosed epithelial ovarian cancer and 523 control women selected either by random digit dialing or through lists of residents. Use of body powders was assessed through personal interview and the exposure odds ratio (OR) for the use of talc in genital hygiene was calculated. Cases were more likely than controls (45% vs. 36%) to have used talc as a body powder in some manner, and the excess was confined to patients who used talc on the perineum directly or as a dusting powder to underwear or sanitary napkins. Relative to women who never used body powder or used it only in non-genital areas, the OR (and 95% confidence interval) associated with genital exposure to talc was 1.60 (1.18 and 2.15) after adjustment for age, study location, parity, oral contraceptive use, body mass index and family history of breast or ovarian cancer. Exposure prior to rather than after a first livebirth appeared to be more harmful, and the association was most apparent for komen with invasive serous cancers and least apparent for those with mucinous tumors. We conclude that there is a significant association between the use of talc in genital hygiene and risk of epithelial ovarian cancer that, when viewed in perspective of published data on this association, warrants more formal public health warnings. Int. J. Cancer 81:351–356, 1999.

© 1999 Wiley-Liss, Inc.

An association between the use of tale in genital hygiene and ovarian cancer was first examined in an epidemiologic study in 1982 (Cramer et al., 1982). An elevated odds ratio for genital tale exposure was observed in this study, in 8 of the largest subsequent epidemiological studies (Whittemore et al., 1983; Booth et al., 1989; Harlow et al., 1992; Chen et al., 1992; Purdie et al., 1995; Shushan et al., 1996; Cook et al., 1997; Chang and Risch, 1997) and in a study of borderline tumors (Harlow and Weiss, 1989). Only 3 smaller studies reported a null association (Hartge et al., 1983; Rosenblatt et al., 1992, Tzonou et al., 1993). Despite this consistency, the association is still viewed with skepticism based upon weak odds ratios, poor dose-response relationships and an incomplete understanding of the biological mechanism by which tale might lead to ovarian cancer. We have completed a large population-based case-control study of ovarian cancer which offers new perspectives on the validity of the tale and ovarian cancer association

MATERIAL AND METHODS

We conducted a population-based case-control study of women with newly diagnosed ovarian cancer who resided in eastern Massachusetts (MA) or New Hampshire (NH). Women with ovarian cancer were identified through hospital tumor boards and statewide cancer registries. Between 5/92 and 3/97, 1,080 cases of ovarian cancer were identified. After excluding 203 cases who had died or moved, had no telephone, did not speak English or had a non-ovarian primary tumor after review, 877 women remained eligible. Physicians denied permission to contact 126 (14%) of these women, and 136 cases (16%) declined to participate. Our

analysis is based upon data from 563 cases with epithelial ovarian cancer, including those with tumors of borderline malignancy,

We identified control women using random digit dialing (RDD) in which the sampling unit for an interviewed case comprised the 99 telephone numbers generated from the first 5 digits of her telephone number plus all remaining combinations of the last 2 digits (excluding the case's own number). These numbers were listed in random order and called to screen households for potential controls who were within 4 years of the age of the case. Excluding business and non-working numbers, approximately 5,400 calls yielded 10% of households in which the household member declined to provide a household census and 80% of households in which an age and sex matched control for a case could not be made or a potential control was ineligible because of a prior oophorectomy. Of the remaining 10% of households screened with a potential eligible control, 72% agreed to participate. RDD proved inefficient for identifying controls over age 60 in MA since a substantially greater number of households needed to be screened to obtain an older control. Except in NH where complete listings of residents were unavailable, we chose to identify older controls in MA by randomly selecting women through use of lists (townbooks) of all residents in towns by name, age, and address according to precinct. We matched older controls to cases by community and age within 4 years based on the townbooks. Of 328 sampled townbook controls, 21% could not be reached, 18% were ineligible and 30% declined to participate. This analysis includes a total of 523 RDD and townbook controls.

In introducing the study to potential cases and controls, specific hypotheses including the talc association were not discussed. After written informed consent, we assessed demographic information, menstrual and reproductive history, medical and family history and personal habits using an in-person interview. We assessed exposures occurring prior to a "reference date," defined as I year before the date of diagnosis for cases and the date of interview for controls. We asked whether women had "regularly used tale, baby, or deodorizing powders dusted or sprayed" to feet, arms or other non-genital areas, to the genital or rectal area, on sanitary napkins, or on underwear, with the latter 3 methods defined as "genital exposure" and either no use or use in non-genital areas defined as "no genital exposure," A husband's use of powder in his genital area was also assessed. Age at first use, types of powder(s) used, applications per month and total years of use in genital hygiene were assessed in talc users. We did not assess potential talc exposure from diaphragms or condoms, exposures not found to be associated with ovarian cancer in our previous studies (Cramer et al., 1982; Harlow et al., 1992).

Grant sponsor: National Cancer Institute; Grant number: R01 Ca54419.

*Correspondence to: Ob-Gyn Epidemiology Center, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA 02115, USA. Fax: (617) 732-4899. E-mail: DWCramer@bics.bwh.harvard.edu

Received 28 August 1998; Revised 19 November 1998

Plaintiff's Exhibit No.
P-107

TABLE I – PERINEAL TALC EXPOSURE¹ IN RELATION TO OVARIAN CANCER RISK BY CHARACTERISTICS OF STUDY PARTICIPANTS

			Cases Controls				
15 42 miles	Total	Tale exposure (%)	Total	Talc expesure (%)	Ago- adjusted ² OR	(95% C.I.)	
Age		_			-	- 12	
<50	266	66 (24.8)	262	43 (16.4)	1.68	(1.09, 2.58)	
≥50	297	86 (29.0)		52 (19.9)	1.64	(1.11, 2.43)	
Study center		((,	11 -	(,	-
MA	433	126 (29.1)	411	85 (20.7)	1.56	(1.14, 2.14)	
NH	130	26 (20.0)		10 (8.9)	2.49	(1.14, 5.45)	Y4.12
Education		20 (20.0)		10 (0.5)	15 3 5	(111 1, 511 5)	
≤12	218	58 (26.6)	171	28 (16.4)	1.79	(1.08, 2.97)	
>12	344	93 (27.0)		67 (19.0)	1.59	(1.10, 2.27)	
Marital status	5	22 (27.0)	332	0. (15,0)		(1.10, 2.21)	
Never married	110	31 (28.2)	61	10 (16.4)	1.77	(0.78, 4.00)	
Ever married	453	121 (26.7)		85 (18.4)	1.62	(1.18, 2.22)	
Religion	455	121 (20.1)	102	05 (10.4)	1.02	(1.10, 2.22)	
Jewish	54	18 (33.3)	44	10 (22.7)	1.69	(0.68, 4.18)	
Non-Jewish	509	134 (26.3)	479		1.63	(1.20, 2.22)	
Weight	20)	134 (20.3)	7/7	05 (17.0)	1.05	(1.20, 2.22)	
<140	237	57 (24.0)	247	40 (16.2)	1.60	(1.02, 2.53)	
≥140 ≥140	326	95 (29.1)		55 (20.0)	1.65	(1.13, 2.42)	
Use of OCs (months)	320	93 (29.1)	213	33 (20.0)	1.05	(1.13, 2.42)	
<3 or never	334	98 (29.3)	247	52 (21.0)	1.55	(1.06, 2.28)	
≥3	229	54 (23.6)	276		1.67		
Number of liveborn children	229	34 (23.0)	270	43 (13.0)	1.07	(1.07, 2.61)	
0	185	55 (29.7)	100	20 (18.9)	1 (5	(0.02.2.00)	
1–2	212		106		1.65	(0.92, 2.98)	200
		49 (23.1)	209	34 (16.3)	1.56	(0.95, 2.54)	
3+	166	48 (28.9)	208	41 (19.7)	1.69	(1.04, 2.75)	
Prior tubal ligation	400	105 (05 5)	405	76 (17.4)			
No	488	135 (27.7)		76 (17.4)	1.80	(1.31, 2.47)	
Yes	75	17 (22.7)	86	19 (22.1)	0.98	(0.46, 2.08)	
Prior hysterectomy	*20	100 (0.5.)	405		4 40		
No	529	139 (26.3)		88 (18.1)	1.60	(1.18, 2.16)	
Yes ³	34	13 (38.2)	36	7 (19.4)	2.61	(0.88, 7.78)	0.00
Family history of breast or ovarian cancer							
No	481	132 (27.4)		87 (18.8)	1.59	(1.17, 2.17)	
Yes	82	20 (24.4)	61	8 (13.1)	2.21	(0.89, 5.48)	

OR: odds ratio; CI: confidence interval; OCs; oral contraceptives.—'Sources of perineal tale exposure include dusting of undetwear, diaptragms, sanitary napkins and/or dusting of genital area.—'Adjusted for age as a continuous variable.—'Excludes those with tubal ligation prior to hysterectomy,

For all cases studied, we reviewed pathology reports and sought slides in any instance where there was a discrepancy between histologic description and final diagnosis. After completing the review, cases were grouped according to the following histologic categories: serous cancers (including serous cystadenocarcinomas and surface papillary carcinomas), mucinous cancers, endometrioid and clear cell cancers, including mixed mesodermal or mixed epithelial with an endometrioid or clear cell component) and undifferentiated or other cancers. According to Young et al. (1994), serous tumors tend to be either borderline or invasive and seldom display a mixture while borderline and invasive grades often intermingle within other histologic types, especially the mucinous tumors. Based on this tendency, only serous borderline tumors were distinguished from invasive cancers when considering odds ratios by histologic type and grade.

Since matching was performed as the most convenient means for selecting controls comparable to cases in age and geographic locale and not as the principal means of controlling for confounding, matching was not preserved in the analysis. We analyzed our data by constructing frequency counts of cases and controls by study variables and by calculating crude odds ratios (OR). We then used unconditional logistic regression to adjust for the matching variables including age (continuous), study site (MA, NH), body mass index (continuous), which might have influenced likelihood of using body powder, and for variables strongly linked to ovarian cancer risk such as parity (0, 1), oral contraceptive use (never or <3 months, >3 months) and family history of breast or ovarian cancer (no, yes) and tubal ligation (no, yes). Most analyses were

performed by using the SAS system (SAS Institute, Cary, NC). Tests for linear trend were performed using the likelihood ratio test with continuous forms of the tale variables. Frequency counts from studies included in our review of published studies were entered into STATA (College Station, TX) to compute crude and combined odds ratios.

RESULTS

Table I summarizes data regarding how cases and controls differed demographically and by known risk factors for ovarian cancer, how these same variables influenced genital tale exposure among controls and how the association between tale use in the genital area and ovarian cancer varied among strata. Controls were more likely than cases to have gone beyond high school, to have married, to have had children and to have used oral contraceptives. In examining the frequency of tale use among controls, only study location significantly influenced likelihood of genital tale exposure. Women from New Hampshire were less likely to have used tale in the genital area compared to women from Massachusetts. Ovarian cancer cases in almost all strata were more likely to have used powder genitally compared to controls, with corresponding elevated odds ratios. A notable exception was the lack of an association between tale use and ovarian cancer among women who reported having had a tubal ligation.

Table II shows adjusted odds ratios by manner, type and frequency of powder use. A greater percentage of cases had regularly used powder in some manner compared to the controls.

TABLE II – ADJUSTED ODDS RATIOS FOR OVARIAN CANCER ASSOCIATED WITH TYPES AND FREQUENCY OF POWDER USE

Type of personal use	Cases Number (%)	Controls Number (%)	Adjusted OR!	(95% C.L)
No personal use	312 (55.4)	334 (63.9)	1.0	
Use, non-genital areas	99 (17.6)	94 (18.0)	1.08	(0.77, 1.50)
Use, dusting perineum	71 (12.6)	51 (9.8)	1,45	(0.97, 2.18)
Use, dusting sanitary napkin	20 (3.6)	12 (2.3)	1.45	(0.68, 3.09)
Use, dusting underwear	8 (1.4)	6 (1.2)	1.21	(0.40, 3.64)
Multiple uses genital area Genital use	53 (9.4)	26 (5.0)	2.15	(1.30, 3.57)
No personal genital exposure	411 (73.0)	428 (81.8)	1.0	
Any personal genital exposure	152 (27.0)	95 (18.2)	1.60	(1.18, 2.15)
Longest used type of powder2	(2)	70 (10.2)	2,00	()
No genital use	411 (73.4)	428 (81.8)	1.0	
Talc	148 (26.4)	92 (17.6)	1.69	(1.26, 2.27)
Comstarch	1 (0.2)	3 (0.6)	0.31	(0.03, 3.01)
Husband use3.1	- (/	- ()	200	(,
No	291 (87.6)	346 (92.0)	1.0	
Yes	41 (12.4)	30 (8.00)	1.52	(0.92, 2.52)
Frequency of use per month4	(,-,	(-11-7)		(-11-)
<30	64 (11.5)	28 (5.4)	2.21	(1.37, 3.56)
30-39	59 (10.6)	51 (9.8)	1.17	(0.78, 1.76)
40+	23 (9.8)	15 (2.9)	1.57	(0.80, 3.10)

¹Adjusted for age (continuous), study center (MA, NH), tubal ligation (ever, never), BMI (continuous), parity (0, ≥1), OC use (<3 months, ≥3 months), and primary relative with breast or ovarian cancer (yes, no) and other categories of genital talc use, except where noted. Adjusted for age (continuous), study center (MA, NH), and tubal ligation (ever, never) and other powder. Among martied women with no personal genital talc use. Total of all uses in the genital area.

Relative to those with no use of a body powder, those who used powder only in non-genital areas did not have an increased risk of ovarian cancer [OR=1.08 (0.77 and 1.50)]. However, elevated ORs and (95% CI) were observed for women who directly powdered the genital or rectal area [1.45 (0.97 and 2.18)]; who dusted sanitary napkins: 1.45 (0.68 and 3.09); who dusted underwear [1.21 (0.40 and 3.64)] and who used powder in multiple ways in the genital area [2.15 (1.30 and 3.57)]. There was a significant excess of cases who regularly used powder in some manner in the genital area, and the adjusted OR was similar whether the non exposed referent group was considered to be women with no use of talc anywhere [OR= 1.58, (1.16 and 2.16)] or women with no genital use including those who used it as a body powder in non-genital areas [OR = 1.60 (1.18 and 2.15)]. Few of the women in our study reported use of cornstarch rather than a talc-based powder leading to an imprecise and non-significant OR for ovarian cancer risk associated with its use in the genital area. Among married women who never personally used talc in the genital area, there was an increase of borderline significance in ovarian cancer risk for women whose husbands had used tale in their genital area [OR=1.52 (0.92, 2.52)]. When we examined all methods of genital talc use (except exposure from a husband), we found that most of those who used tale had 30 or more applications per month, but there was no apparent trend for increasing risk for ovarian cancer with increasing number of monthly applications.

Table III examines risk for ovarian cancer associated with ordinal categories related to duration or intensity of tale exposure in the genital area relative to women who never used tale or who used it only in non-genital areas. No clear linear trend was apparent in ORs for categories of age at first use, years of use or total applications. To examine dose response, each of these variables was used as a continuous variable in multivariate models. Linear trends were significant only in those models that included women who were not exposed. To duplicate an analysis performed in a previous report (Harlow et al., 1992), we examined total applications censored by excluding use after closure of the female tract or during non-ovulatory years. Although the ORs for the categories displayed a trend, once again only the multivariate model including the non-genitally exposed revealed a significant trend.

Table IV presents a more detailed analysis of the effect of genital use of tale in women who had no pregnancies at all, in women who had a pregnancy not resulting in a liveborn and in women with a liveborn pregnancy. In the latter 2 groups, we examined risk for ovarian cancer with the timing of tale use in relation to the first pregnancy. Genital tale use that began after a first pregnancy appeared to be associated with lower risk compared to use which began before the first pregnancy. The effect was more apparent among those with a liveborn. Eighty-five of 374 parous cases used at least some tale prior to their first liveborn compared to 64 of 416 parous controls, leading to an adjusted OR (95% CI) of 1.58 (1.10 and 2.29). In contrast, 8 of 378 parous cases used tale only after their first livebirth compared to 10 of 417 parous controls, leading to an adjusted OR (95% CI) of 0.97 (0.38 and 2.50) for ovarian cancer associated with tale use after a first livebirth.

Table V shows the average age and use of genital talc for all controls and for cases by histologic type of ovarian cancer. Average age differed by histologic type but did not account for the differences in ORs. The odd ratio for genital talc use was greatest (and significant) for invasive serous tumors and less than 1 only for mucinous tumors (invasive and borderline combined) after adjustment for age and other covariates.

DISCUSSION

Consistent with four recent case-control studies of ovarian cancer (Purdie et al., 1995, Sushan et al., 1996, Cook et al., 1997, Chang and Risch, 1997), our results demonstrate a significant association between the use of tale in genital hygiene and risk for ovarian cancer. In our discussion, we will examine whether this association satisfies traditional criteria for a causal association including consistency and strength of the association, potential biases, dose response and biological credibility.

Figure 1 summarizes data on risk for ovarian cancer with any genital use of talc from 14 case-control studies including this one. The combined odds ratio and 95% CI is 1.36 (1.24 and 1.49), which is statistically significant. Odds ratios deviating most from the pooled value were observed in the smaller studies, and the test for heterogeneity was not significant (p=0.085). Thus, the criteria for

CRAMER ET AL.

TABLE III – ADJUSTED ODDS RATIOS FOR OVARIAN CANCER ASSOCIATED WITH GENITAL USE OF TALC

Type of exposure —	Cas	Controls	Adjusted	(95% C.I.)	
	Number (%)	Number (%)	ÖR¹		
No genital use	411 (73.0)	428 (81.8)	1.0		
Age at first use	` '	` '			
<20	97 (17.4)	67 (12.8)	1.46	(1.03, 2.07)	
20-25	36 (6.5)	18 (3.4)	1.87	(1.03, 3.39)	
>25	13 (2.3)	9 (1.7)	1.54	(0.64, 3.72)	
p-value for linear trend is 0.				(//	
Years of use					
<20	55 (9.9)	31 (5.9)	1.86	(1.16, 3.00)	
		26 (5.0)	1.33	(0,76, 2.30)	
20-30	32 [3.0]				
20-30 >30	32 (5.8) 59 (10.6)				
>30	59 (10.6)	37 (7.1)	1.44	(0.91, 2.26)	
>30 p-value for linear trend is 0.	59 (10.6)	37 (7.1)	1.44	(0.91, 2.26)	
>30 p-value for linear trend is 0. exposed.	59 (10.6)	37 (7.1)	1.44	(0.91, 2.26)	
>30 p-value for linear trend is 0. exposed. Total applications	59 (10.6) 477 excluding non-g	37 (7.1) enitally exposed a	1.44 nd 0.062 inc	(0.91, 2.26) luding non-genitally	
>30 p-value for linear trend is 0. exposed. Total applications <3000	59 (10.6) 477 excluding non-g 51 (9.2)	37 (7.1) genitally exposed a 27 (5.2)	1.44 nd 0.062 inc	(0.91, 2.26) luding non-genitally (1.12, 3.03)	
>30 p-value for linear trend is 0. exposed. Total applications <3000 3000-10,000	59 (10.6) 477 excluding non-g 51 (9.2) 36 (6.5)	37 (7.1) enitally exposed a 27 (5.2) 28 (5.4)	1.44 nd 0.062 inc 1.84 1.43	(0.91, 2.26) inding non-genitally (1.12, 3.03) (0.84, 2.41)	
>30 p-value for linear trend is 0. exposed. Total applications <3000 3000-10,000 >10,000	59 (10.6) 477 excluding non-g 51 (9.2) 36 (6.5) 59 (10.6)	37 (7.1) enitally exposed a 27 (5.2) 28 (5.4) 39 (7.5)	1.44 nd 0.062 inc 1.84 1.43 1.43	(0.91, 2.26) huding non-genitally (1.12, 3.03) (0.84, 2.41) (0.92, 2.22)	
>30 p-value for linear trend is 0. exposed. Total applications <3000 3000-10,000 >10,000 p-value for linear trend is 0.	59 (10.6) 477 excluding non-g 51 (9.2) 36 (6.5) 59 (10.6)	37 (7.1) enitally exposed a 27 (5.2) 28 (5.4) 39 (7.5)	1.44 nd 0.062 inc 1.84 1.43 1.43	(0.91, 2.26) huding non-genitally (1.12, 3.03) (0.84, 2.41) (0.92, 2.22)	
>30 p-value for linear trend is 0. exposed. Total applications <3000 3000-10,000 >10,000 p-value for linear trend is 0. exposed.	59 (10.6) 477 excluding non-g 51 (9.2) 36 (6.5) 59 (10.6)	37 (7.1) enitally exposed a 27 (5.2) 28 (5.4) 39 (7.5)	1.44 nd 0.062 inc 1.84 1.43 1.43	(0.91, 2.26) huding non-genitally (1.12, 3.03) (0.84, 2.41) (0.92, 2.22)	
>30 p-value for linear trend is 0. exposed. Total applications <3000 3000-10,000 >10,000 p-value for linear trend is 0. exposed. Applications censored ²	59 (10.6) 477 excluding non-g 51 (9.2) 36 (6.5) 59 (10.6) 164 excluding non-g	37 (7.1) enitally exposed a 27 (5.2) 28 (5.4) 39 (7.5) enitally exposed a	1.44 nd 0.062 inc 1.84 1.43 1.43 nd 0.472 inc	(0.91, 2.26) luding non-genitally (1.12, 3.03) (0.84, 2.41) (0.92, 2.22) luding non-genitally	
>30 p-value for linear trend is 0. exposed. Total applications <3000 3000-10,000 >10,000 p-value for linear trend is 0. exposed.	59 (10.6) 477 excluding non-g 51 (9.2) 36 (6.5) 59 (10.6)	37 (7.1) enitally exposed a 27 (5.2) 28 (5.4) 39 (7.5)	1.44 nd 0.062 inc 1.84 1.43 1.43	(0.91, 2.26) huding non-genitally (1.12, 3.03) (0.84, 2.41) (0.92, 2.22)	

¹Adjusted for age (continuous), study center (MA, NH), BMI (continuous), primary relative with breast or ovarian cancer (yes, no), parity (0, ≥1), OC use (<3 months, ≥3 months), tubal ligation, and other categories of genital tale use, except where noted. ∃Excludes applications following hysterectomy or tubal ligation and applications during pregnancy and periods of OC use. Adjusted for age (continuous), study center (MA, NH), BMI (continuous) and primary relative with breast or ovarian cancer (yes, no).

TABLE IV - EVER USE OF TALC IN THE GENITAL AREA IN RELATION TO PREGNANCY AND CHILDBIRTH

		Cases	(8/)	Controls				
Group	Tetni	Number exposed	(%) exposed	Total	Number exposed	(%) exposed	Adjusted OR	95% C.I.
Nulligravid ^t	145	42	(29.0)	82	17	(20.7)	1.48	(0.76, 2.86)
Nulliparous1 prior to first pregnancy	40	13	(32.5)	24	3	(12.5)	2.80	(0.64, 12.20)
Nulliparous only after first pregnancy	40	2	(5.0)	24	1	(4.2)	1.24	(0.10, 15.32)
Parous prior to first livebirth	374	85	(22.7)	416	64	(15.4)	1.58	(1.10, 2.29)
Parous ² only after first livebirth	378	8	(2.12)	417	10	(2.40)	0.97	(0.38, 2.50)

¹Adjusted for age (continuous), study center (MA, NH), BMI (continuous) and primary relative with breast or ovarian cancer (yes, no).—²Adjusted for age (continuous), study center (MA, NH), BMI (continuous), primary relative with breast or ovarian cancer (yes, no) and tubal ligation.

TABLE V - HISTORY OF GENITAL TALC USE AND ASSOCIATED ODDS RATIOS BY HISTOLOGIC TYPE AND GRADE

Histologic type/grade	Total	Average age	Any use of genital tale	No use of genital tale	Adjusted OR ¹	(95% CI)
Controls	523	49.3	95	428	1.0	
Histologic type/grade						
Serous borderline	86	41.8	23	63	1.38	(0.82, 2.31)
Serous invasive	229	54.5	72	157	1.70	(1.22, 2.39)
Mucinous	83	46.7	16	67	0.79	(0.44, 1.40)
Endometrioid/clear cell	130	53.9	31	99	1.04	(0.67, 1.61)
Undifferentiated	35	52,9	10	25	1.44	(0.67, 3.08)

¹Adjusted for age (continuous), study center (MA, NH), primary relative with breast or ovarian cancer (yes, no), BMI (continuous), parity (0, ≥1), OC use (<3 months, ≥3 months) and tubal ligation (ever, never).

consistency of the association appear to be satisfied. A summary odds ratio of 1.36 suggests that between 10 and 11% of ovarian cancers in these populations are attributable to the genital use of talc depending upon whether the average control exposure of 36% or average case exposure of 43% is considered.

Despite the consistency noted above, the relatively weak odds ratios observed could reflect potential biases, especially recall and confounding. Recall bias is possible because tale exposure in these

studies is based on personal recollection. However, recall bias seems more likely to affect exposures that have occurred over a short term than those that have occurred over a long term. Since average duration of tale use exceeded 20 years in both cases and controls in our current study, genital tale exposure may be less likely to be subject to recall bias. Furthermore, if publicity regarding the association correlated with selective recall, one might expect a trend for cases from more recent studies to report higher




FIGURE 1 - Exposure rates, crude odds ratios and confidence intervals for case-control studies of genital tale use and ovarian cancer.

exposure rates, but the exposure rates noted in Figure 1 do not suggest this is the case. It also seems reasonable that selective recall would lead to cases reporting all types of tale exposure more frequently than controls, but our study found that cases did not report a significant excess of tale use in non-genital areas compared to controls. Finally, if recall accounted for the association, one would expect little variation in the odds ratios by histologic type of ovarian cancer which appears not to be the case from Table V. Our study found the greatest risk to be associated with invasive serous tumors, OR=1.70 (1.22 and 2.39). Cook et al. (1997) found tale use to be most strongly associated with serous and unclassified cancers, although Chang and Risch (1997) found endometrioid cancers to be more strongly linked with tale use.

Regarding potential bias from confounding, we found no evidence that genital tale exposure varied by key risk factors for ovarian cancer such as age, parity or OC use and little variability of the association by these and other variables (Table II). Chang and Risch (1997) adjusted for age, parity, breastfeeding, oral contraceptive use, tubal ligation or hysterectomy and family history and also found the association to persist. Characteristics such as body odor or excessive perspiration might represent subtle constitutional features that might predispose to both tale use and ovarian cancer, but adjusting for BMI should control for these effects. In addition, 2 previous studies (Cook et al., 1997; Chang and Risch, 1997), and our current study found no evidence of elevated risk associated with genital use of a cornstarch based-powder, although in all of these studies the exposure was infrequent and the OR and confidence interval was wide. Further studies would be valuable since this observation suggests that type of powder used may be more important than underlying reason for use,

The most obvious weakness in the argument for biologic credibility of the tale and ovarian cancer association is the lack of a clear dose response. Most tale and ovarian cancer studies that have addressed dose response, including this one, have failed to

demonstrate consistent dose response relationships with measures of the intensity of the exposure, especially when the trend is examined among users only. In attempting to address this weakness, we point out that it is difficult to quantify the amount of powder actually used and degree of perineal dusting that might constitute an "application of talc." Another factor that may affect the dose-response relationship is whether use occurred at a time when the female tract was open. There is evidence from several studies that the tale/ovarian cancer association is modified by closure of the female tract as a result of tubal ligation or hysterectomy (Harlow et al., 1992; Chang and Risch, 1997; Green et al., 1997). We have also proposed that talc use during periods of ovulation may carry greater risk, based on the hypothesis that ovarian surface epithelial disruption and repair accompanying ovulation might allow tale to become entrapped within the inclusion cysts that form with ovulation.

Our current study also suggests that a term pregnancy may affect the relationship between tale and ovarian cancer in a manner that may be independent of ovulation. We observed that the association between tale and ovarian cancer was more apparent in women who used talc prior to a first liveborn pregnancy compared to those who used it only after a first liveborn pregnancy. This may suggest that ovarian tissue that has not (yet) gone through a pregnancy may be more susceptible to talc-induced damage than tissue that has undergone a pregnancy. A possible biologic explanation for this may involve an ovarian change, known as decidual reaction, that occurs during pregnancy. The decidual reaction refers to differentiation of stromal cells that occurs primarily in the endometrium of the pregnant uterus but which also may be seen in the fallopian tubes, pelvic peritoneum and ovarian surface (Herr et al., 1978). Studies to determine whether the decidual reaction alters the susceptibility of ovaries (or pelvic peritoneum) to tale-induced damage may be informative.

Although we do not know precisely how use of talc in the genital area might induce ovarian cancer, some key elements supporting the biologic plausibility of the association have been established. It has been demonstrated that inert particles contaminating the vagina can reach the ovaries (Venter and Iturralde, 1979). Talc has been found in both normal and malignant ovarian tissue (Henderson et al., 1979), although Heller et al. (1996) reported a poor correlation between the amount of talc in the ovaries and personal history of talc use. The patency of the female tract and the nature of ovarian cancer as a surface epithelial (mesothelial) lesion make the ovary a target for foreign body carcinogenesis. Indeed, human ovarian cancer has been demonstrated to be a consequence of occupational asbestos exposure (Keal, 1960). Talc, as a chemical relative of asbestos, appears able to induce histologic changes that are similar to those of asbestos, at least in the lungs (Kleinfeld et al., 1967). Biologic credibility for an association would be strengthened by an animal model, but an experiment capturing all of the potential factors in the human "model" would be very difficult. These elements include chronicity of the exposure, anatomic and physiologic uniqueness of women, effects of pregnancy and potential spread through coitus (as suggested by our finding related to ovarian cancer risk associated with a husband's use of tale). Rodent models seem poorly suited to address these issues because of their infrequent ovulation and the fact that the rodent ovary is encased in a bursal sac.

In summary, we have demonstrated a consistent association between tale and ovarian cancer that appears unlikely to be explained by recall or confounding. The dose-response relationship is weak but improved by considering factors such as closure of the female tract, ovulation and exposure prior to pregnancy, and we have outlined a plausible biologic rationale for this association. We estimate that avoidance of tale in genital hygiene might reduce the occurrence of a highly lethal form of cancer by at least 10%. Balanced against what are primarily aesthetic reasons for using tale in genital hygiene, the risk benefit decision is not complex. Appropriate warnings should be provided to women about the potential risks of regular use of tale in the genital area.

REFERENCES

BOOTH, M., BERAL, V. and SMOTH, P., Risk factors for ovarian cancer: a case-control study. *Brit. J. Cancer*, 60, 592-598 (1989).

CHANG, S. and RISCH, H., Perineal tale exposure and risk of ovarian carcinoma. *Cancer*, 79, 2396-2401 (1997).

CHEN, Y., Wu, P.C., LANG, J.H., GE, W.Y., HARTGE, P. and BRINTON, L.A., Risk factors for epithelial ovarian cancer in Bejing, China. Int. J. Epidemiol., 21, 23-29 (1992).

COOK, L.S., KAMB, M.L. and Weiss, N.S., Perineal powder exposure and the risk of ovarian cancer. *Amer. J. Epidemiol.*, 145, 459-465 (1997).

CRAMER, D.W., WELCH, W.R., SCULLY, R.E. and WOJCIECHOWSKI, C.A., Ovarian cancer and tale. Cancer, 50, 372-376 (1982).

GREEN, A., PURDIE, D., BAIN, C., SISKIND, V., RUSSELL, P., QUINN, M., WARD, B. and SUNVEY OF WOMEN'S HEALTH STUDY GROUP, Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Int. J. Cancer, 71, 948–951 (1997).

HARLOW, B.L., CRAMER, D.W., BELL, D.A. and WELCH, W.R., Perineal exposure to tale and ovarian cancer risk. Obstet. Gynecol., 80, 19-26 (1992).

HARLOW, B.L. and WEISS, N.S. A case-control study of borderline ovarian tumors: The influence of perineal exposure to tale. *Amer. J. Epidemiol.*, 130, 390-394 (1989).

HARTGE, P., HOOVER, R., LESHER, L.P. and MCGOWAN, L., Tale and ovarian cancer (letter). J. Amer. Med. Ass., 250, 1844 (1983).

HELLER, D.S., WESTHOFF, C., GORDON, R.E. and KATZ, N., The relationship between perineal cosmetic talc usage and ovarian talc particle burden. *Amer. J. Obstet. Gynecol.*, 174, 1507–1510 (1996).

HENDERSON, W., HAMILTON, T. and GRIFFITH, K., Tale in normal and malignant ovarian tissue. *Lancet*, 5, 449 (1979).

HERR, J.C., HEIDGER, P.M., SCOTT, J.R., ANDERSON, J.W., CURET, L.B. and MOSSMAN, H.W., Decidual cells in the human ovary at term I. Incidence,

gross anatomy and ultrastructural features of merocrine secretion. Amer. J. Anat., 152, 7–28 (1978).

Keal, E.E., Asbestosis and abdominal neoplasms. Lancet, 2: 1211-1216 (1960).

KLEINFELD, MESSITE, J., KOOYMAN, O. and ZAKI, M.H., Mortality among tale miners and millers in New York State, Arch Environ. Health, 14, 663-667 (1967).

PURDIE, D., GREEN, A., BAIN, C., SISKIND, V., WARD, B., HACKER, N., QUINN, M., WRIGHT, G., RUSSELL, P. and SUSIL, B., Reproductive and other factors and risk of epithelial ovarian cancer; an Australian case-control study. Int. J. Cancer, 6, 678-684 (1995).

ROSENBLATT, K.A., SZKLO, M. and ROSENSHEIN, N.B., Mineral fiber exposure and the development of ovarian cancer. *Gynecol. Oncol.*, 45, 20–25 (1992).

SHUSHAN, A., PALTIEL, O., ISCOVICH, J., ELCHALKAL, U., PERETZ, T. and SCHENKER, J.G., Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil. Steril., 65, 13–18 (1996).

TZONOU, A., POLYCHRONOPOULOU, A., HSIEH, C.C., REBELAKOS, A., KARA-KATSANI, A. and TRICHOPOULOS, D., Hair dyes, analgesies, tranquilizers and petineal tale application as risk factors for ovarian cancer. *Int. J. Cancer*, 55, 508–510 (1993).

VENTER, P.F. and ITURRALDE, M., Migration of particulate radioactive tracer from the vagina to the peritoneal cavity and ovaries. S. Afr. med J., 55, 917-209 (1979).

WHITTEMORE, A.S., Wu, M.L., PAFFENBAROER, R.S., SARLES, D.L., KAM-BERT, J.B., GROSSER, S., JUNG, D.L., BALLEN, S. and HENDRICKSON, M., Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder tobacce, alcohol, and coffice. Amer. J. Epidemiol., 128, 1228–40 (1988).

YOUNG, R.H., CLEMENT, P.B. and SCULLY, R.E., The Ovary (chapter 53). In Stemberg, S.S. (ed.), Diagnostic Surgical Pathology (2nd Ed.), p. 2213, Raven Press, New York (1994).